CTOs on the Move

Cloud Pharmaceuticals

www.cloudpharmaceuticals.com

 
Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Neponset Controls Inc

Neponset Controls Inc is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novo Nordisk

Headquartered in Denmark, Novo Nordisk has more than 5,000 employees in the United States – representing 16% of the total workforce. From our insulin product manufacturing facility in Clayton, , North Carolina, to our Research and Development Center in Seattle, Washington we bring value to communities across the country in a variety of ways.   Our newly constructed LEED-certified building in Plainsboro, New Jersey, is modeled on principles of functionality, innovation, openness, quality, and aesthetics-offering a space that promotes collaboration and creativity.

Sisters of Saint Joseph of Philadelphia

We are a community of approximately 825 women religious. Originally founded in 1650 in LePuy, France, the Sisters of Saint Joseph came to Philadelphia in 1847. Through our many ministries, including educations, healthcare, social services and parish m...

Dicerna

Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.